The Obesity Society commends FDA for ending obesity drug shortages; social media influencers spread misleading info regarding medical tests; this drug may prevent migraines in adolescents – Morning Medical Update

The Obesity Society commends FDA for ending obesity drug shortages

The Obesity Society (TOS) commends the U.S. Food and Drug Administration (FDA) for resolving shortages of key obesity and diabetes medications, including Novo Nordisk’s Wegovy and Ozempic, as well as Eli Lilly’s Zepbound, back in December. With supply restored, TOS calls on the FDA to enforce regulations against unauthorized compounded versions of these drugs, which may pose safety risks to patients. Marc-André Cornier, MD, FTOS, president, TOS, emphasizes the importance of using FDA-approved treatments, urging healthcare providers and patients to prioritize rigorously tested medications to ensure safe and effective care.

Social media influencers are spreading misleading information regarding medical tests, study finds

A University of Sydney-led study, published in JAMA Network Open, revealed that influencers on Instagram and TikTok are promoting misleading information about controversial medical tests to millions of followers. Analyzing nearly 1,000 social media posts, researchers found that most lacked scientific evidence, emphasized benefits while ignoring risks, and were often financially motivated. Tests such as full-body MRIs, genetic cancer screenings, anti-mullerian hormone (AMH) fertility tests, and testosterone tests were frequently promoted despite limited medical support.

“Given that social media platforms like Instagram are moving away from fact-checking their content, the need for stronger regulation to prevent misleading medical information has gained urgency,” said Josh Zadro, PhD, senior researcher and co-author from the University of Sydney.

This drug may help prevent migraines in children and teens

A preliminary study released Wednesday, which will be presented at the upcoming American Academy of Neurology’s 77th Annual Meeting, suggests that zonisamide, a drug typically used to treat seizures, may reduce migraine frequency in children and teens. Researchers found that among 256 young migraine patients prescribed zonisamide, the median number of headache days per month dropped from 18 to six. The greatest reduction was observed in patients who took the drug for at least two months.